Nervous System Symptoms Associated With COVID 19

University Hospital, Toulouse99 enrolled

Overview

This study aim to prospectively evaluate the neuropsychiatric symptoms of patients infected with the SARS-CoV-2 virus by a standardized neuropsychiatric examination : the global CASE scale (Clinical Assessment Scale in Autoimmune Encephalitis), and the prevalence of disturbances of consciousness, focal neurological deficit, cognitive impairment, headache, anosmia, sleep disturbances, impaired autonomic nervous system and peritraumatic stress.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Enrollment

Conditions

Covid19

Interventions

NEURO +OTHER

The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score : * The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005) * the Peri traumatic distress inventory (Jehel et al., 2005) * and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004) Neuro + patients will also have a Brain MRI, cerebrospinal fluid analysis, EEG, as well as an ambulatory sleep recording and electromyography depending on the symptoms observed.

NEURO -OTHER

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Being hospitalized at the Toulouse University Hospital for a COVID-19 infection proven by a probable PCR or COVID-type examination on the chest scan * Have given oral consent for the collection of clinical neurological data * Be in a clinical state compatible with a 30-minute neurological examination * Be French-speaking * Be affiliated to a Social Security scheme Exclusion Criteria: * Refusal of the neurological examination * History of neurological pathology at a severe stage * Pregnant or breastfeeding woman * Persons with tutors or curators

Locations (1)

CHU Toulouse

Toulouse, France

Outcomes

Primary Outcomes

percentage of patients in the Neuro + and Neuro- groups

The percentage is deducted from the score on a global scale by the Clinical Assessment Scale in Autoimmune Between 0 and 1, patients will be classified in the Neuro group, if this score is greater than or equal to 2, patients will be classified in the Neuro + group.

Time frame: Baseline T0 : inclusion visit

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.